Description and Brand Names
Drug information provided by: IBM Micromedex
US Brand Name
Lutetium Lu 177 vipivotide tetraxetan injection is used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has spread to other parts of the body) in patients who have received other cancer treatments (eg, androgen receptor pathway inhibition, taxane-based chemotherapy).
Lutetium Lu 177 vipivotide tetraxetan is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents, which may be used to find and treat certain diseases or to study the function of the body's organs.
This medicine is to be given only by or under the direct supervision of a doctor with specialized training in nuclear medicine.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2023
Copyright © 2023 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.